Citations

Clear

750 citation(s) found for "Lowe, Val".

CU PET Aβ and Tau Positive Individuals Show Impairment in MoCA Delayed Recall
Felix, Cynthia , Snitz, Beth E. , Abbas, Sarah , Oliveira, Markley, Lemaire, Peter Charles , Kollasserry, Felix Joy, Rebok, George W. , Amaral, Lívia , Lowe, Val J. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Tudorascu, Dana , Jagust, William J., Baker, Suzanne L. , Ferreira, Pâmela C.L. , Rodrigues, Matheus Scarpatto , Bauer‐Negrini, Guilherme , Povala, Guilherme , Medeiros, Marina Scop , Soares, Carolina , Aguzzoli, Cristiano Schaffer , Bellaver, Bruna , Lussier, Firoza Zubeida , Pascual, Belén , Gordon, Brian A. , Klunk, William E. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.094075 Get It

AbstractBackgroundIdentification of cognitively unimpaired (CU) individuals who may progress to mild cognitive impairment (MCI), is a pressing issue in the Alzheimer’s disease (AD) field, since therapeutic interventions may be more effective in the absence of cognitive impairment and neurodegeneration. CU individuals positive for amyloid and tau PET are very likely in the AD pathway. In out‐patient cognitive screening, we use rapid and simple tests such as The Montreal Cognitive Assessment (MoCA) ‐ a composite of executive, visuospatial, naming, attention, language, abstraction, delayed recall, and orientation performances. We hypothesize that sub‐categorizing the CU group based on the presence of amyloid (A) and tau (T) pathologies, as measured by PET, can reveal subtle cognitive deficits, even in a clinical test with low sensitivity such as MoCA.MethodWe included 88 CU [defined as CDR global score of 0] older adults with available head‐to‐head MK6240 tau‐PET and Flortaucipir tracers from the ongoing HEAD multi‐site observational study. They also underwent Amyloid PET imaging using PiB or NAV4694. MoCA testing was done around the imaging time. To increase similarity with clinical practice, Amyloid and Tau PET positivity was defined using visual reads. Based on tracer uptake status, we categorized the individuals into A‐T‐, A‐T+, A+T‐ and A‐T‐ groups. Unpaired t‐test and one‐way ANOVA were used to test for significant differences between groups.Result2‐tailed p‐values were significant between the A‐T‐ group and the A+T+ group for MoCA total score [p: 0.0025 and p: 0.0025]. When we stratified MoCA in the different cognitive domains, we found that the results were driven by MoCA (memory) Delayed Recall score [p: 0.0007 and p: 0.0162]. A‐T+ vs A+T+ was also significant [p: 0.0099] for MoCA Delayed Recall. Both tau tracers (MK6240 and Flortaucipir) showed similar performance for determining T+ and identifying cognitive decline.ConclusionMoCA, a simple and commonly administered in‐office neuropsychological test, can detect subtle cognitive dysfunction in CU older adults who are Aß and tau positive (A+/T+). These CU A+/T+ individuals are likely on the path to developing AD dementia.
TAU EXACERBATES THE DEVELOPMENT OF DISTINCT NEUROPSYCHIATRIC SYMPTOMS IN LATE BRAAK STAGE – THE HEAD STUDY
Amaral, Lívia , Zalzale, Hussein, Abbas, Sarah , Tudorascu, Dana , Lowe, Val J. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Baker, Suzanne L. , Aguzzoli, Cristiano Schaffer , Povala, Guilherme , Ferreira, Pâmela C.L. , Lussier, Firoza Zubeida , Bauer‐Negrini, Guilherme , Soares, Carolina , Ferrari‐Souza, João Pedro , Bellaver, Bruna , Rohden, Francieli , Leffa, Douglas Teixeira , Schilling, Lucas Porcello , Zimmer, Eduardo Rigon , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.094042 Get It

AbstractBackgroundRecent studies showed that neuroinflammation plays a key role in triggering specific neuropsychiatric symptoms (NPS), such as irritability and agitation, in individuals with Alzheimer’s disease (AD). While prior studies showed an association between tau pathology and all NPS domains, the extent to which tau influences each specific NPS domain remains unclear. Here, we aim to investigate the association of tau and NPS domains in the AD continuum. We hypothesize that tau plays a comparatively greater effect on the emergence of psychotic symptoms compared to other NPS domains.MethodWe assessed 56 individuals (21 cognitively unimpaired (CU), 23 MCI, and 12 AD dementia) from the HEAD study who underwent clinical assessments with the Neuropsychiatry Inventory Questionnaire (NPI‐Q) and had positron emission tomography (PET) for amyloid‐ß (Aß) ([18F]AZD4694 or [11C]PiB), and tau tangles ([18F]MK6240) at the same visit. We selected individuals with an NPI‐Q total score =1. Tau SUVR values were tailored with a mask from Braak stages I‐VI, using the inferior cerebellar gray matter as reference region. Leave‐one‐out voxel wise and linear regression tested the association between each NPI‐Q domain and biomarkers accounting for age, sex, cognitive status, and study site.ResultCI individuals had significantly higher NPI‐Q score and Braak VI PET SUVR than CU individuals (Table 1). NPI‐Q score was significantly associated with tau‐PET in the periRolandic and supplementary motor cortex (Figures 1A). Linear regression showed that NPI‐Q associates with tau‐PET in the Braak stage VI (Figure 1B). Leave‐one‐out regression analysis revealed that delusions, motor disturbances, and anxiety contributed most to the association between tau‐PET and NPS (Figure 2A, C). These domains presented a higher magnitude of association compared to each other NPI‐Q domain (Figure 2B). Notably, irritability, agitation, and disinhibition exerted a negative effect to the association, emphasizing that tau may not play a role in the development of these symptoms (Figure 2A, D)ConclusionOur study supports previous evidence suggesting that irritability and agitation may not be triggered by tau, but rather by other pathological process such as neuroinflammation. These findings provide additional rationale for the therapeutics aiming to mitigate irritability and agitation in AD patients.
Longitudinal multicenter head‐to‐head harmonization of tau‐PET tracers: an overview of the HEAD study cohort
Amaral, Lívia , Cehula, Juli, Fine, Devin J, Lemaire, Peter Charles , Bloomquist, Madeleine , Lowe, Val J. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Tudorascu, Dana , Jagust, William J. , Baker, Suzanne L. , Lussier, Firoza Zubeida , Povala, Guilherme , Bauer‐Negrini, Guilherme , Fine, Devin J, Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Klunk, William E. , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.094013 Get It

AbstractBackgroundStandardizing tau pathology quantification in vivo is challenged by differences in binding characteristics between tau‐PET tracers. The HEAD study aims to generate a leading, longitudinal head‐to‐head dataset of MK‐6240, Flortaucipir, RO948, and PI‐2620 tau‐PET to harmonize these tracers' outcomes and develop tools allowing for the generalization of findings across large studies and trials. Here, we present current advancements in building the HEAD study cohort and dataset.MethodsThe HEAD study is managed at the University of Pittsburgh. HEAD comprises several sites across the US and Canada in which 620 subjects (young, cognitively unimpaired, mild cognitive impairment, and Alzheimer’s disease (AD)) will undergo tau‐PET with at least two tracers, amyloid‐PET with PiB or NAV4694, MRI, blood collection, and standardized neuropsychological testing at baseline and at 18‐month follow‐up. PET and MRI acquisition parameters are based on ADNI4 protocols and neuropsychological testing employs the NACC Uniform Data Set. The National Centralized Repository for AD serves as the biorepository for blood samples and the Laboratory of Neuroimaging provides a centralized database for imaging and neuropsychological archiving. PET data is reconstructed to maximize cross‐scanner harmonization and is processed uniformly similarly to ADNI4 PET.ResultsIn one year of active enrollment (Jan 2023‐Jan 2024), 362 participants were enrolled at six active sites; over 80% of participants completed neuropsychological testing and MRI, and over 70% completed Flortaucipir, MK‐6240, and amyloid‐PET, with a mean tau‐PET acquisition window of 29.1 days. RO948 and PI‐2620 tau‐PET are additionally acquired in a subset currently including 41 participants (Fig.1). Current HEAD cohort demographics including age, sex, underrepresented populations, and group distributions, APOEe4 carrier status, and amyloid positivity are shown in Fig.2. A case of a subject with AD with all 4 tau‐PET tracers acquired head‐to‐head within 49 days is shown in Fig.3.ConclusionThe HEAD study represents a continued effort in the optimization of AD imaging biomarkers. Baseline data collection is projected to be completed in 2024; results being generated by multiple groups from this dataset will provide novel and crucial guidance on the use of tau‐PET tracers in research, clinical trials, and prospectively in clinical practice.
Alzheimer's disease staging with [18F]MK6240 and [18F]Flortaucipir ‐ the HEAD study
Amaral, Lívia , Zalzale, Hussein, Madeiros, Marina Scop, Cehula, Juli, Bloomquist, Madeleine , Oliveira, Markley, Felix, Cynthia , Abbas, Sarah , Zimmer, Eduardo R., Lowe, Val J. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Tudorascu, Dana , Jagust, William J. , Baker, Suzanne L. , Medeiros, Marina Scop , Soares, Carolina , Povala, Guilherme , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Ferreira, Pâmela C.L. , Bellaver, Bruna , Madeiros, Marina Scop, Cehula, Juli, Rodrigues, Matheus Scarpatto , Ruppert, Emma Patrice , Zimmer, Eduardo Rigon , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Klunk, William E. , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.094006 Get It

AbstractBackgroundUtilizing PET amyloid‐beta (Aß) and tau for staging Alzheimer’s Disease (AD) has demonstrated potential in identifying individuals with varying degrees of disease severity, applicable to both clinical trials and practice. However, the diverse binding characteristics of tau tracers pose challenges to the application of this staging across different ligands. In this study, we evaluate a novel staging framework proposed by the AA working group, employing Aß PET and either [18F]MK6240 or [18F]Flortaucipir in individuals participating in a head‐to‐head study of tau PET tracers. This will provide insights into the robustness of this framework when applied across different tau ligands.MethodWe evaluated 154 people (89 CU and 65 CI), with MK6240, Flortaucipir, Aß‐PET, MRI. SUVRs used inferior cerebellar gray as reference. Participants were categorized in Aß positivity(A), using visual read, and tau positivity (T) in medial temporal lobe(MTL) and neocortex(NEO). Tau MTL(TMTL) and NEO positivity were defined as average +3 SD of youngs. NEO moderate(TMOD) and high(THIGH) was defined as below and above median SUVR of NEO‐positive individuals. Individuals were grouped as: A‐T‐, A+T‐, A+TMTL+(early), A+TMOD+(intermediary), and A+THIGH+(advanced).ResultsWe found that the distribution of the number of individuals across the five AD stages was comparable when using both MK6240 and Flortaucipir tracers (Figure 1). However, upon examining the concordance within each group, we found a low concordance of 30% (3/10) between tracers in the early tau stage (A+TMTL+). Concordance increased in the intermediary stage A+TMOD+, with a rate of 65% (9/14), and further increased to 79% (11/14) in the advanced stage (A+THIGH+). The A+T‐ group exhibited the highest concordance between tracer results, at 95% (21/22).ConclusionOur findings indicate that the application of this framework across different populations using different tau tracers can lead to a compatible distribution among groups. However, in a direct comparison, we noted that this did not necessarily result in high concordance between groups, as group shifts were observed that depended on the cutoffs used (data not shown). These results emphasize the necessity for harmonization of tau PET tracers prior to their utilization for stage determination.
Relationships between PET and blood plasma biomarkers in corticobasal syndrome
Alnobani, Alla, Graff‐Radford, Jonathan, Schwarz, Christopher G., Lowe, Val J. , Kanekiyo, Takahisa , Josephs, Keith A. , Whitwell, Jennifer L. , Singh, Neha Atulkumar , Graff‐Radford, Jonathan , Machulda, Mary M. , Mielke, Michelle M. , Schwarz, Christopher G. , Senjem, Matthew L. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.094001 Get It

AbstractBackgroundCorticobasal syndrome (CBS) is a progressive neurodegenerative syndrome that can result from several underlying neuropathologies, including Alzheimer’s disease (AD). Little is known about the utility of blood plasma measures to predict PET biomarker confirmed AD in CBS.MethodEighteen CBS patients (8 PET Aß+; 10 PET Aß‐) and 8 cognitively unimpaired Aß‐ individuals (CU) were recruited by the Neurodegenerative Research group from the Department of Neurology, Mayo Clinic, Rochester, MN, underwent Aß (Pittsburgh Compound‐B) and tau (18F‐flortaucipir) PET and provided a blood sample. Blood plasma analysis was performed to assess p‐tau 181, total tau, Aß 42/40, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) using the Quanterix Simoa platform. Plasma concentrations were compared between Aß‐, and Aß+ CBS and controls using Kruskal‐Wallis corrected for multiple comparisons using Dunn’s test, with effect size measured with area under the receiver operating characteristic curve (AUROC) analysis. Spearman correlations were calculated to assess relationships between plasma concentrations and Aß and tau PET uptake.ResultThe CBS Aß+ group showed reduced Aß42/40 ratio, with elevated p‐tau 181, GFAP and NfL plasma concentrations compared to CU, while the CBS Aß‐ group only showed elevated NfL concentration compared to CU (Figure 1). Both p‐tau 181 (AUROC=0.95) and GFAP (AUROC=0.91) plasma concentrations were able to differentiate CBS Aß‐ from CBS Aß+. Plasma p‐tau 181 and GFAP concentrations showed a positive correlation to both Aß and tau PET uptake, and the Aß42/40 ratio showed a negative correlation to Aß PET uptake (Figure 2). No correlations were observed between NfL and Aß and tau PET.ConclusionThis study supports the use of plasma p‐tau 181 and GFAP to detect AD in CBS, while NfL shows potential as a nonspecific disease biomarker of CBS regardless of underlying pathology. Plasma concentrations of these biomarkers may potentially be incorporated into clinical trials targeting CBS patients with underlying AD pathology.
A Large Public Release of Clinical and Imaging Data from the Mayo Clinic Study of Aging
Prakaashana, Carl M., Przybelski, Scott A. , Christenson, Luke R., Wiliams, Josie M., Gunter, Jeffrey L. , Fields, Julie A. , Lowe, Val J. , Graff‐Radford, Jonathan , Petersen, Ronald C. , Schwarz, Christopher G. , Kremers, Walter K. , Wiliams, Josie M., Senjem, Matthew L. , Arani, Arvin , Reid, Robert I. , Machulda, Mary M. , Kantarci, Kejal , Vemuri, Prashanthi , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093966 Get It

AbstractBackgroundThe Mayo Clinic Study of Aging (MCSA) is a longitudinal, population‐based study of residents of Olmsted County, Minnesota, USA. MCSA is releasing de‐identified clinical and imaging data on GAAIN.org to benefit the research community.MethodWe included longitudinal clinical data from all participants of the Mayo Clinic Study of Aging 30‐90 years of age (average 70.0y) through the first 15 years of the study. Clinical data includes age, sex, self‐reported race/ethnicity, APoE4 allele status, cognitive impairment status (normal, MCI, dementia, or other), height, weight, blood pressure, multi‐domain neuropsychological scores, neuroimaging summary measurements, medications, cardiovascular risk factors, social activity, sleep, mood/anxiety, functional measures, and more. For our initial release of imaging data, we selected the first imaging timepoint acquired on 3T GE MRI scanners and amyloid (PiB) PET during the same visit, from all available imaging participants 50‐90 years of age (average 70.7y). Currently, we included 3D T1‐weighted (MPRAGE) MRI (1x1x1.2mm3), T2‐weighted FLAIR MRI (0.85x0.85x3.6mm3), diffusion MRI (2.7mm resolution with 41 directions at b=1000 and 5 b=0), and numeric cortical global SUVR and Centiloid values from PiB PET scans at 40‐60 minutes post‐injection. All images are released in DICOM format and thoroughly de‐identified using CTP while ensuring preservation of necessary fields for analyses. T1‐weighted and T2‐FLAIR MRI were also de‐faced (identifiable face imagery was removed and replaced with an average) using mri_reface version 0.3.3 to further protect participants’ privacy, and all de‐faced images were visually inspected by a trained data scientist for quality assurance.ResultThe first phase of our public data release includes clinical data from 5925 unique participants from the Mayo Clinic Study of Aging (MCSA), each ranging from 1‐12 visits at roughly 15‐month intervals, and three MRI sequences (T1‐w, T2‐w‐FLAIR, and diffusion) from 1802 unique participants. Demographic summaries are given in Table 1.ConclusionThis large, richly characterized, de‐identified clinical and imaging dataset is available to the research community at https://www.gaaindata.org/partner/MCSA, and it is suitable for a wide range of research uses. Additional data will be released over time, including de‐faced amyloid PET images.
Distinct Spatial Patterns for White Matter Microstructure Changes in an Aging and Alzheimer's Disease Cohort
Tian, Jianqiao , Raghavan, Sheelakumari , Przybelski, Scott A. , Graff‐Radford, Jonathan, Lowe, Val J. , Petersen, Ronald C. , Cogswell, Petrice M. , Reid, Robert I. , Schwarz, Christopher G. , Graff‐Radford, Jonathan , Kantarci, Kejal , Knopman, David S. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093924 Get It

AbstractBackgroundWhite matter (WM) damage is seen with neurodegenerative and cerebrovascular pathologies and contributes to cognitive dysfunction. We hypothesized that there are multiple disease progression patterns in WM microstructural changes related to aging and dementia, and these can be identified using SuStaIn (data‐driven clustering algorithm for disease subtype and stage discovery) on multishell diffusion MRI (NODDI) data. NODDI provides information on cellular tissue architecture – neurite density index (NDI) measures packing density of axons and dendrites, and free water fraction (FWF) measures unrestricted water, e.g., interstitial and cerebrospinal fluid.MethodWe identified 1136 participants (mean age=70 years, 51% male, 40% Aß‐positive, 19% MCI/AD dementia) from the Mayo ADRC and Mayo Clinic Study of Aging. We analyzed NDI and FWF in 55 WM regions. We selected a subset of WM features that monotonically changed with clinical disease progression and then applied the Z‐score SuStaIn algorithm.ResultNDI in seven regions and FWF in six regions survived selection criteria (Figure 1). Noteworthy, the NDI regions were predominantly located in the temporal lobe, while FWF regions were primarily distributed in the frontal and subcortical regions. The SuStaIn algorithm discovered two stable clusters: the NDI‐First (Temporal) and FWF‐First (Frontal) groups (Figure 2). For the NDI‐First group, temporal lobe NDI changed early followed by frontal FWF. The FWF‐First group had the reverse order. There was clear phase separation based on which measure changed first. Stages of the NDI‐First group correlated better with meta‐ROI Tau‐PET SUVR and with MMSE than the FWF‐First group (p<0.01), suggesting that NDI‐First may be indicative of a primarily AD pathway.ConclusionGiven NDI changes are likely degenerative and FWF are suggested to be other processes such as neurodegeneration or inflammatory, the observed changes in the temporal and frontal regions may be due to distinct etiologies, i.e., neurodegenerative in the temporal lobes vs. vascular dysfunction often observed in the frontal lobes. The SuStaIn algorithm showed promise in discovering disease subtypes of WM microstructural changes. Further work is needed to understand the mechanistic basis of these observed changes and integrate WM changes for differential etiology identification and disease staging.
Comparison of [18F]MK6240 and [18F]Flortaucipir standardized uptake values (SUVs): the HEAD study
Tsai, Hsin‐Yeh, Tudorascu, Dana , Rahmouni, Nesrine , Servaes, Stijn , Stevenson, Jenna , Lowe, Val J. , Soleimani‐Meigooni, David N. , Oh, Hwamee , Jagust, William J., Baker, Suzanne L. , Tissot, Cécile , Tsai, Hsin‐Yeh, Lussier, Firoza Zubeida , Therriault, Joseph , Gordon, Brian A. , Pascual, Belén , Klunk, William E. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093894 Get It

AbstractBackgroundDifferences between on‐ and off‐target retention characteristics between [18F]MK6240 and [18F]Flortaucipir (FTP) complicate the harmonization across tracers. Our objective here was to separate the impact of the reference region by evaluating correlations between [18F]MK6240 (MK) and [18F]FTP standard uptake values (SUVs).MethodParticipants (Figure 1, n=90) received an amyloid‐β (Aβ) PET scan ([11C]PIB or [18F]NAV4694) and two tau‐PET scans: [18F]MK (90‐110 minutes post‐injection) and [18F]FTP (80‐100 minutes post‐injection). For all PET scans, the individual frames were realigned, averaged, and co‐registered to a Freesurfer 7.1‐segmented T1‐MPRAGE. SUVs were calculated in the reference region (inferior cerebellar gray), on‐target regions (entorhinal cortex, hippocampus, Braak III, Braak IV, Braak V, Braak VI) and off‐target regions (caudate, pallidum, putamen, thalamus, cerebellar white matter, choroid plexus, meninges, eroded white matter). We examined correlations between [18F]MK and [18F]FTP SUV values as a function of Aβ status, as well as their associations with age.ResultAll correlations (Figure 2) were significant at p<0.001. The interaction with Aβ status was significant for hippocampus, BraakIII‐V and the metatemporal region. In Aβ+ participants, [18F]FTP and [18F]MK6240 have similar SUVs in on‐target regions with a slope close to 1 except for in hippocampus and Braak VI. However, [18F]FTP SUVs, on average, were greater than [18F]MK SUVs in Aβ+ and Aβ‐ subjects in the reference region and all off‐target regions except for meninges, and in Aβ‐ subjects in the on‐target regions. Age correlated with [18F]FTP SUVs in Aβ‐ subjects in all regions (except the reference region, Braak VI and meninges) and [18F]MK SUVs in putamen and pallidum, but this correlation was only significant (p<0.01) when young and old subjects were included.ConclusionDespite [18F]MK’s higher affinity for tau and SUVR dynamic range being twice that of [18F]FTP, the SUVs in on‐target regions are similar. The higher [18F]FTP signal in the reference region appears to be the contributing factor to the lower dynamic range. The higher [18F]FTP signal in on‐target regions for Aβ‐ subjects may reflect the presence of off‐target signals in these subjects. Taking off‐target signals into account should improve correlations between the two tracers, especially when measuring the earliest deposition of tau.
Comparing regional and global diffusion MRI markers as biomarkers of VCID
Raghavan, Sheelakumari , Przybelski, Scott A. , Kamykowski, Michael G. , Lesnick, Timothy G. , Graff‐Radford, Jonathan , Lowe, Val J. , Knopman, David S. , Petersen, Ronald C., Reid, Robert I. , Knopman, David S. , Jack, Clifford R. , Petersen, Ronald C. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093870 Get It

AbstractBackgroundQuantifying white matter using diffusion MRI (dMRI) has been proposed for measuring early microstructural tissue changes due to cerebral small vessel disease and aid in quantifying vascular contributions to cognitive impairment and dementia (VCID). Our goal was to compare the usefulness of longitudinal white matter changes in the commonly available diffusion MRI measures for VCID prevention trials.MethodWe included 718 participants over 50 years of age (mean age: 71.1(9.6) years) from the Mayo Clinic Study of Aging, a population‐based sample, with at least two dMRI scans and structural imaging. We computed the commonly available single‐shell dMRI measures (fractional anisotropy, mean diffusivity, and two MarkVCID measures ‐ free water and peak‐width skeletonized mean diffusivity [PSMD]) at each time point. We tested for voxel‐wise associations between dMRI markers and vascular risk measured by cardiovascular metabolic condition (CMC) and observed a region‐specific dependance across all dMRI measures. Using both global and regional dMRI measures, we (i) examined the longitudinal association of dMRI measures with cognition and (ii) computed sample size estimates for a hypothetical clinical trial. We also included white matter hyperintensities (WMH) and our previously proposed composite vascular white matter score (combination of WMH and fractional anisotropy of the genu) as a comparison.ResultVascular risk was associated with all single shell dMRI measures in the genu of the corpus callosum, which we included as a regional dMRI marker for comparison (Figure 1). All dMRI markers correlated with cognitive performance longitudinally (Table 1) and had comparable sample size estimates required for hypothetical VCID clinical trials (Figure 2). Further, global free water and the composite vascular white matter score had the smallest sample size estimates.ConclusionAll commonly used dMRI markers had significant frontal lobe changes due to vascular risk. Both global and regional corpus callosum dMRI markers were sensitive to longitudinal cognitive decline, suggesting their utility in measuring the slowing down of VCID. The composite vascular white matter score, global free water, and WMH show promise as VCID biomarkers. Further work is needed to validate these markers on multiple populations.
Comparison of tau‐PET tracers for in vivo Braak staging: the HEAD Study
Macedo, Arthur C. , Rahmouni, Nesrine , Servaes, Stijn , Wang, Yi‐Ting , Socualaya, Kely Monica Quispialaya, Lowe, Val J. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Baker, Suzanne L. , Therriault, Joseph , Tissot, Cécile , Lussier, Firoza Zubeida , Arias, Jaime Fernández , Hosseini, Seyyed Ali , Ferreira, Pâmela C.L. , Bellaver, Bruna , Ferrari‐Souza, João Pedro , Aguzzoli, Cristiano Schaffer , Povala, Guilherme , Pascual, Belén , Gordon, Brian A. , Pascoal, Tharick Ali , Rosa-Neto, Pedro

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093737 Get It

AbstractBackgroundTau‐PET tracers allow for in vivo Braak staging of individuals in the Alzheimer’s disease (AD) continuum. The impact of tracers’ characteristics for Braak staging using tau‐PET remains unclear. Therefore, we performed a head‐to‐head comparison of Braak staging using first‐ and second‐generation tau‐PET tracers.MethodWe assessed 51 cognitively unimpaired (CU) and 49 cognitively impaired participants (mean [SD] age 69.4 [7.5] years) with at least two tau‐PET ligands ([18F]MK6240, [18F]AV1451, and/or [18F]RO948) at McGill University, as part of the HEAD study. We calculated standardized uptake value ratios (SUVR) in Braak‐like regions of interest (ROI) for each ligand and investigated their association using Spearman’s correlation. Thresholds defined the presence of tauopathy in each Braak ROI, which was used to assign a Braak stage to each participant. Finally, we assessed the agreement between the Braak staging provided by each tracer, both for the traditional (using separate Braak stages – 0, I, II, III, IV, V, and VI) and simplified (using joint Braak stages – 0, I‐II, III‐IV, and V‐VI) frameworks.ResultIn all Braak ROIs, we found positive correlations between the SUVR values of the three tracers (Fig. 1). The strongest correlation was between [18F]MK6240 and [18F]RO948 in Braak II (r=0.94), and the weakest between [18F]AV1451 and [18F]RO948 in VI (r=0.51). Inter‐tracer agreement regarding the latest stage of abnormality was substantial or nearly perfect between pairs of tracers but moderate between the three tracers (Fig. 2A). The simplified framework presented greater agreement compared to traditional Braak staging, except between [18F]MK6240 and [18F]RO948. At the ROI level, the lowest agreements were observed for Braak II and I‐II, when [18F]MK6240 and [18F]RO948 were compared to [18F]AV1451 (Fig. 2B‐C). [18F]AV1451 had the highest probability of overestimating the Braak stage assigned by [18F]MK6240 and by [18F]RO948, especially at earlier stages (Fig. 3).ConclusionThe ligands presented moderate to nearly perfect agreement for in vivo staging of AD severity. Off‐target binding of [18F]AV1451 to the choroid plexus might explain disagreements at early stages. Overall, slight improvements in agreements were achieved with the simplified framework, as observed in histopathological staging.